Find clinical trials for Non-Hodgkin Lymphoma in Montréal, QC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Montréal, QC, CAN:
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non...
Phase 1
Montreal, Quebec, Canada and 12 other locations
immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...
Phase 1
Montréal, Quebec, Canada and 2 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Montreal, Quebec, Canada and 37 other locations
with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...
Phase 1, Phase 2
Montreal, Quebec, Canada and 28 other locations
participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...
Phase 3
Montreal, Quebec, Canada and 72 other locations
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...
Phase 1, Phase 2
Montréal, Quebec, Canada and 48 other locations
This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled de...
Phase 1
Montréal, Quebec, Canada and 3 other locations
evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non...
Phase 2
Montréal, Quebec, Canada and 119 other locations
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma...
Phase 1
Montreal, Quebec, Canada and 39 other locations
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...
Phase 1
Montreal, Quebec, Canada and 23 other locations
Clinical trials
Research sites
Resources
Legal